Arcadia Biosciences says FDA completes safety review of Verdeca's HB4 soybeans
Arcadia Biosciences and Bioceres S.A. announced their joint venture, Verdeca, received notification that the U.S. Food and Drug Administration has completed its full review of the company's safety evaluation for HB4 soybeans. The FDA's notice to Verdeca allows products derived from HB4 soybeans to be used commercially in human food and animal feed. This is a major milestone in the development of commercial soybean seed products based on the HB4 stress tolerance trait. Completion of the FDA's review is another key regulatory achievement in the approval process for Verdeca's HB4 drought stress tolerance trait. The trait has already been approved in Argentina by the Ministry of Agriculture, Livestock and Fisheries. Verdeca has also submitted an environmental safety data petition to the US Department of Agriculture, and this submission is currently under review. Upon completion, the USDA is expected to issue a Determination on Nonregulated Status, which will complete the approval processes in the US and allow for commercial production of HB4 soybeans.